MFAP5 inhibits the malignant progression of endometrial cancer cells in vitro
- PMID: 39759103
- PMCID: PMC11699556
- DOI: 10.1515/biol-2022-0990
MFAP5 inhibits the malignant progression of endometrial cancer cells in vitro
Abstract
To investigate the biological role of MFAP5 in endometrial cancer (EC). HEC-1-A and Ishikawa cells overexpressing MFAP5 were created. Cell proliferation, apoptosis, migration, and invasion were evaluated using CCK8, colony formation, flow cytometry, and transwell assays. A western blot was used to analyze the expression of markers affiliated with the epithelial-mesenchymal transition process and AKT/mTOR pathway. As a result, MFAP5 was found to be down-regulated in EC. Overexpression of MFAP5 suppressed proliferation and promoted apoptosis of HEC-1-A and Ishikawa cells, as evidenced by the inhibition of cell viability and colony formation, and the increase in cell apoptosis rate. Besides, overexpression of MFAP5 attenuated the abilities of cell migration and invasion, as well as reduced MMP2 and MMP9 protein expression. Furthermore, E-cadherin protein level was elevated, while N-cadherin and α-SMA protein levels were decreased, and the phosphorylation of AKT and mTOR was reduced in cells overexpressing MFAP5. Our findings indicate that MFAP5 overexpression inhibits the malignant behaviors of EC cells, possibly by blocking the AKT/mTOR pathway, suggesting that MFAP5 may be a new therapeutic target for EC.
Keywords: AKT/mTOR; EMT; MFAP5; endometrial cancer; proliferation.
© 2024 the author(s), published by De Gruyter.
Conflict of interest statement
Conflict of interest: Authors state no conflict of interest.
Figures






Similar articles
-
MicroRNA-183 induces epithelial-mesenchymal transition and promotes endometrial cancer cell migration and invasion in by targeting CPEB1.J Cell Biochem. 2018 Nov;119(10):8123-8137. doi: 10.1002/jcb.26763. Epub 2018 Jun 20. J Cell Biochem. 2018. Retraction in: J Cell Biochem. 2021 Nov;122 Suppl 1:S104. doi: 10.1002/jcb.30084. PMID: 29923214 Retracted.
-
LncRNA TUG1 promotes the migration and invasion in type I endometrial carcinoma cells by regulating E-N cadherin switch.Taiwan J Obstet Gynecol. 2022 Sep;61(5):780-787. doi: 10.1016/j.tjog.2022.03.045. Taiwan J Obstet Gynecol. 2022. PMID: 36088044
-
MiR-101 reduces cell proliferation and invasion and enhances apoptosis in endometrial cancer via regulating PI3K/Akt/mTOR.Cancer Biomark. 2017 Dec 12;21(1):179-186. doi: 10.3233/CBM-170620. Cancer Biomark. 2017. Retraction in: Cancer Biomark. 2021;30(2):275. doi: 10.3233/CBM-210950. PMID: 29081412 Retracted.
-
Heat Shock Protein B7 Inhibits the Progression of Endometrial Carcinoma by Inhibiting PI3K/AKT/mTOR Pathway.Reprod Sci. 2023 Feb;30(2):590-600. doi: 10.1007/s43032-022-01041-7. Epub 2022 Jul 20. Reprod Sci. 2023. PMID: 35859224
-
Knockdown of Trop2 inhibits proliferation and migration and induces apoptosis of endometrial cancer cells via AKT/β-catenin pathway.Cell Biochem Funct. 2020 Mar;38(2):141-148. doi: 10.1002/cbf.3450. Epub 2020 Jan 22. Cell Biochem Funct. 2020. PMID: 31967350
References
-
- Cai Y, Wang B, Xu W, Liu K, Gao Y, Guo C, et al. Endometrial cancer: genetic, metabolic characteristics, therapeutic strategies and nanomedicine. Curr Med Chem. 2021;28(42):8755–81. - PubMed
-
- Sun KX, Zheng RS, Zuo J, Zhang SW, Zeng HM, Wang SM, et al. The incidence and mortality of endometrial cancer in China, 2015. Zhonghua yi xue za zhi. 2022;102(26):1987–92. - PubMed
LinkOut - more resources
Full Text Sources
Research Materials
Miscellaneous